QC
LCTX icon

Quadrature Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Quadrature Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2K Buy
+10,046
New +$13.9K ﹤0.01% 1540
2026
Q1 		– Sell
-30,632
Closed -$51.2K – 1653
2025
Q4 		$51.2K Sell
30,632
-148,399
-83% -$257K ﹤0.01% 1175
2025
Q3 		$304K Buy
+179,031
New +$212K ﹤0.01% 666

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Quadrature Capital's LCTX Position: Q2 2026 in Review

Quadrature Capital opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 10,046 shares worth $13.2K. The stake represents ﹤0.01% of the portfolio and ranks #1540 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in LCTX as recently as Q4 2025.

Quadrature Capital first reported a position in LCTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $304K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Quadrature Capital held 10,046 shares of Lineage Cell Therapeutics worth $13.2K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Quadrature Capital position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1540 holding.
  • Quadrature Capital first reported a position in Lineage Cell Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Lineage Cell Therapeutics position peaked at $304K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.